Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13:18 | Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference | 1 | GlobeNewswire (USA) | ||
Di | Processa Pharmaceuticals Inc expected to post a loss of $1.60 a share - Earnings Preview | 1 | Reuters | ||
Mo | Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting | 2 | GlobeNewswire (USA) | ||
21.02. | Processa Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
21.02. | Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference | 1 | GlobeNewswire (USA) | ||
14.02. | Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference | 1 | GlobeNewswire (USA) | ||
09.02. | How Is The Market Feeling About Processa Pharma? | - | Benzinga.com | ||
08.02. | Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying | 2 | Benzinga.com | ||
06.02. | Processa Pharmaceuticals regains Nasdaq compliance | - | Investing.com | ||
06.02. | Processa Pharmaceuticals regains compliance with Nasdaq minimum bid price rule | 2 | Seeking Alpha | ||
06.02. | Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule | 157 | GlobeNewswire (Europe) | HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation... ► Artikel lesen | |
06.02. | Processa Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
01.02. | Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering | 1 | GlobeNewswire (USA) | ||
29.01. | Panbela Therapeutics, Processa Pharmaceuticals among healthcare movers | 8 | Seeking Alpha | ||
29.01. | PCSA, TCBP and NXU among pre-market losers | 11 | Seeking Alpha | ||
26.01. | What's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today? | 2 | Benzinga.com | ||
26.01. | Processa Pharmaceuticals prices discounted stock and warrants offering to raise $7M | 3 | Seeking Alpha | ||
26.01. | TCBP and PCSA among pre-market losers | 11 | Seeking Alpha | ||
26.01. | Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering | 1 | GlobeNewswire (USA) | ||
26.01. | ACON, PCSA and CORZ among pre-market losers | 14 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVO NORDISK | 118,50 | -0,05 % | Dividendenbekanntmachungen (22.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALTRIA GROUP INC US02209S1033 0,98 USD 0,9022 EUR CARL ZEISS MEDITEC AG DE0005313704 - 1,1 EUR CPH CHEMIE+PAPIER HOLDING AG CH0001624714 4... ► Artikel lesen | |
GILEAD SCIENCES | 68,00 | +0,86 % | Aktienmarkt: Gilead Sciences-Aktie tritt auf der Stelle (67,6671 €) | Am US-amerikanischen Aktienmarkt ist der Anteilsschein von Gilead Sciences gegenwärtig unauffällig. Zuletzt zahlten Investoren für das Wertpapier 73,50 US-Dollar. Kaum verändert im Vergleich zu der... ► Artikel lesen | |
TEVA | 13,250 | -0,38 % | Teva UK and Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalised Medicines | Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicines.
Under the agreement, Closed Loop Medicine a leading TechBio... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 386,10 | +0,14 % | Vertex Gets FDA Nod Of IND For VX-407 For Autosomal Dominant Polycystic Kidney Disease | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Thursday, Vertex Pharmaceuticals Inc. (VRTX) announced that the FDA has cleared the Investigational New Drug Application or IND for VX-407 for the treatment... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 20,200 | +4,66 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 13,560 | +7,28 % | Astria Therapeutics Reports Positive Initial Results From ALPHA-STAR Trial | ||
OPKO HEALTH | 0,975 | -2,29 % | Labcorp to buy select assets of OPKO Health's unit; OPKO shares up | ||
APONTIS PHARMA | 6,360 | 0,00 % | APONTIS PHARMA: "Eine bessere Performance bei deutlich geringeren Kosten" - CEO Bruno Wohlschlegel exclusiv im Gespräch | Mit einem Kursplus von rund 40 Prozent zählt die Aktie der APONTIS PHARMA AG (ISIN: DE000A3CMGM5) zu den positiven Überraschungen des Börsenjahres 2024. Nach dem Wechsel an der Vorstandsspitze hat der... ► Artikel lesen | |
EXSCIENTIA | 5,250 | -1,87 % | Exscientia plc: Exscientia Business and Financial Update for the Full Year 2023 | Exscientia plc (Nasdaq: EXAI)
Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 112,25 | +0,40 % | Jazz Pharmaceuticals Celebrates International Women's Day | NORTHAMPTON, MA / ACCESSWIRE / March 20, 2024 / Jazz PharmaceuticalsOriginally published by Jazz PharmaceuticalsTo mark International Women's Day, JAWS (Jazz Association of Women Supporters), the affinity... ► Artikel lesen | |
XORTX THERAPEUTICS | 3,420 | +2,70 % | Zweite Chance: Nach Gewinnmitnahmen bietet diese Aktie eine neue Gewinnchance | ||
ROYALTY PHARMA | 28,460 | +1,21 % | Dividendenbekanntmachungen (15.02.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 1,51 USD 1,4074 EUR A10 NETWORKS INC US0021211018 0,06 USD 0,0559 EUR ADVANCED ENERGY INDUSTRIES INC US0079731008 0... ► Artikel lesen | |
TG THERAPEUTICS | 14,200 | -2,67 % | TG Therapeutics, Inc.: TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting | NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating... ► Artikel lesen | |
CATALYST PHARMACEUTICALS | 15,055 | +0,07 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day | ||
CATALENT | 52,10 | 0,00 % | Catalent lays off 130 staffers at massive Indiana facility being sold to Novo Nordisk |